![logo](/logos/DVAX.webp)
Dynavax Technologies Corporation
NASDAQ:DVAX
11.03 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Dynavax Technologies Corporation |
Symbool | DVAX |
Munteenheid | USD |
Prijs | 11.03 |
Beurswaarde | 1,445,415,320 |
Dividendpercentage | 0% |
52-weken bereik | 9.74 - 15.15 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Ryan Spencer |
Website | https://www.dynavax.com |
An error occurred while fetching data.
Over Dynavax Technologies Corporation
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)